COVID-19 Vaccine Development: An Interview With GeoVax

The biotechnology company GeoVax Labs Inc. develops human immunotherapies and vaccines against infectious diseases and cancer. The company recently announced that it is developing vaccine candidates for the prevention/ control of SARS-CoV-2, the virus causing the COVID-19 outbreak, using its GV-MVA-VLPTM vaccine platform. Three vaccines have been designed and are in final steps of purification and characterization. Technology Networks spoke with David Dodd, President and CEO of GeoVax, to learn more about the vaccine candidates, what progress has been made in clinical testing and how the company is working to accelerate vaccine development timeframes. MC: For our readers that may be unfamiliar with GeoVax, please can you tell us about the company and its technology? David Dodd (DD): GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer using a novel and safe viral vector platform (GV-MVA-VLPTM). Important attributes of GeoVax vaccines include single dose, no adjuvant, durable immunity, extensive safety and cost-effective manufacturing. GeoVax’s recombinant Modified Vaccinia Ankara (MVA) vector expresses target proteins on highly immunogenic Virus-Like Particles (VLPs) in the person being vaccinated, resulting in induction of durable immune responses while providing the safety characteristics of the https://www.technologynetworks.com/biopharma/blog/covid-19-vaccine-development-an-interview-with-geovax-332972?utm_campaign=NEWSLETTER_TN_Breaking%20Science%20News&utm_source=hs_email&utm_medium=email&utm_content=85706843&_hsenc=p2ANqtz-8RJSabzu9z3XQNq4NNnDM8zIuf_WHogFGR_HR4RAQOlUA-G0AGew8W7c7hJS83z9_pD9i-7dZqN6PyR8EBSpnxLebEhA&_hsmi=85706843